Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial-Reference-Cited by-同舟云学术

Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial

Published:2020-09-01 Issue:9 Volume:30 Page:1245-1253
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Chen Jiaying¹,Ji Qinghai¹,Bai Chunmei²,Zheng Xiangqian³,Zhang Yuan⁴,Shi Feng⁵,Li Xiaojiang⁶,Tang Pingzhang⁷,Xu Zhengang⁷,Huang Rui⁸,Huang Tao⁹,Pan Yueyin¹⁰,Fan Songhua¹¹,Zhou Jinghong¹¹,Su Weiguo¹¹

Affiliation:

1. Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.

2. Department of Medical Oncology, Chinese Academy of Medical Science, Peking Union Medical College Hospital, Beijing, China.

3. Department of Head and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

4. Department of Head and Neck Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China.

5. Department of Thyroid Medicine, Hunan Cancer Hospital, Changsha, China.

6. Department of Head and Neck Surgery, Yunnan Cancer Hospital, Kunming, China.

7. Department of Head and Neck Surgical Oncology, Cancer Institute (Hospital), Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China

8. Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.

9. Department of Thyroid and Breast Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

10. Tumor Chemotherapy Division, Anhui Province Hospital, Anhui, China.

11. Hutchison MediPharma Ltd., Shanghai, China.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2019.0453

Reference19 articles.

1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

2. Cancer statistics in China, 2015

3. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995

4. 5. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review 1975–2016. Surveillance Research Program of the National Cancer Institute (NCI), Bethesda, MD.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance;Drug Resistance Updates;2024-01

2. Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer;Life;2023-12-22

3. Infiltration of B cell may underlie the contrary sex- and age-related biological behavior of papillary thyroid carcinoma;2023-08-07

4. The Efficacy and Safety of Surufatinib Combined with Anti PD-1 Antibody Toripalimab in Neoadjuvant Treatment of Locally Advanced Differentiated Thyroid Cancer: A Phase II Study;Annals of Surgical Oncology;2023-08-05

5. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-07